A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MYD88, Mutation Analysis
Test CodeMYD88
Alias/See Also
91771
CPT Codes
81305
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
2 mL whole blood • 0.5 mL bone marrow • 6 slides
Other Acceptable Specimens
Whole blood collected in: Sodium heparin (green-top) or ACD-B (yellow-top) tube • 2 mL bone marrow collected in: EDTA (lavender-top) tube or sodium heparin (green-top) tube • Formalin-fixed, paraffin-embedded tissue block • 10 slides tissue submitted in a slide holder • Extracted DNA from CLIA-certified laboratory or cell pellet
Transport Temperature
Room temperature
Specimen Stability
Whole blood and bone marrow
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Paraffin block and slides
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Extracted DNA
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 1 year
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Paraffin block and slides
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Extracted DNA
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 1 year
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Frozen specimens
Methodology
Next Generation Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Monday-Sunday Morning Report available: 7 Days after receipt at the performing laboratory. Add two (2) days for transport.
Reference Range
Not detected
Clinical Significance
Oncogenic mutations in MYD88, in particular the L265P mutation, have been identified as driver mutations in various B-cell lymphomas. The L265P mutation is found in approximately 90% of Waldenstom macroglobulinemia and IgM-expressing lymphoplasmacytic lymphoma (LPL). There is a low incidence of L265P MYD88 mutation in other systemic CD5-negative B-cell lymphoproliferative disorders including atypical chronic lymphocytic leukemia, nodal marginal zone lymphoma (MZL), splenic MZL and mucosa-associated lymphoid tissue (MALT)-type MZL. This next-generation sequencing (NGS) based assay detects clinically significant MYD88 mutations, including the L265P mutation and can be used to help diagnose Waldenstrom macroglobulinemia or IgM-expressing lymphoplasmacytic lymphoma and to help in stratifying or subclassifying patients with IgM monoclonal gammopathy.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: May 4, 2023